PDF DatasheetMouse Anti-IFNG / Interferon Gamma Antibody Product Attributes
IFNG / Interferon Gamma Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in IFNG / Interferon Gamma antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. Low, but measureable presence of IFNG / Interferon Gamma could be seen inadipocytes in mesenchymal tissue, cells in the endometrial stroma in endometrium, cells in the glomeruli in kidney, cells in the tubules in kidney, fibroblasts in skin, glandular cells in the adrenal gland, appendix, cervix, uterine, duodenum, epididymis, gallbladder, parathyroid gland, rectum, seminal vesicle, small intestine and stomach, keratinocytes in skin, Langerhans in skin, Leydig cells in the testis, macrophages in lung, melanocytes in skin, myocytes in heart muscle and skeletal muscle, neuronal cells in the hippocampus, non-germinal center cells in the tonsil, pneumocytes in lung, respiratory epithelial cells in the nasopharynx, smooth muscle cells in the smooth muscle, squamous epithelial cells in the oral mucosa and urothelial cells in the urinary bladder. We were unable to detect IFNG / Interferon Gamma in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of IFNG / Interferon Gamma expression as measured by anti-IFNG / Interferon Gamma antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – |
| IFNG Variability | ++ | ++ | + | ++ | ++ | + | ++ | + | ++ | + | ++ | + | ++ | + | ++ | + | + | + | ++ | + |
| IFNG / Interferon Gamma General Information | |
|---|---|
| Alternate Names | |
| IFNG, Interferon Gamma Protein, EGK_391, IFN-gamma | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | Ifng |
| Entrez Gene ID | 15978 |
| Ensemble Gene ID | ENSMUSG00000055170 |
| RefSeq Protein Accession(s) | NP_032363 |
| RefSeq mRNA Accession(s) | NM_008337 |
| RefSeq Genomic Accession(s) | NC_000076 |
| UniProt ID(s) | P01580 |
| UniGene ID(s) | P01580 |
| Cosmic ID(s) | Ifng |
| KEGG Gene ID(s) | mmu:15978 |
| General Description of IFNG / Interferon Gamma. | |
| The XMG1.2 antibody is specific for mouse Interferon-gamma (IFN-g), a 20 kDa type II cytokine known for its central roles in protection against bacterial or viral pathogens and for its anti-tumor properties. IFN-g is secreted by several types of immune cells which allow the cytokine to modulate innate immunity when secreted by NK and NKT cells, and to function in support of adaptive immunity when secreted by Th1 and CD8+ T cells (CTLs).The XMG1.2 antibody is suitable for detection of intracellular IFN-g protein by flow cytometry. Other formats can be used for quantitative analysis of the secreted protein by ELISA when paired with an appropriate capture antibody. This clone has been reported for neutralization of the functional activity of IFN-g in a variety of assays (use format suitable for functional assays). | |
There are no reviews yet.